A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 29, 2009, Pages 3757-3761

  Etienne Grimaldi, Marie Christine ^a   Renée, Nicole ^a   Izzedine, Hassan ^b   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HPLC; Pharmacokinetics; Sunitinib

Indexed keywords

A-STABILITY; ACTIVE METABOLITES; ANTI-TUMOR ACTIVITIES; BLOOD SAMPLING; HPLC; HPLC ANALYSIS; LIGHT EXPOSURE; LIMIT OF DETECTION; ORGANIC EXTRACTIONS; PHARMACOKINETIC ANALYSIS; RENAL CELL CARCINOMA; RUNTIMES; STEADY STATE; TERT-BUTYL METHYL ETHERS; TYROSINE KINASE; TYROSINE KINASE INHIBITOR; UV DETECTION;

AMINO ACIDS; CHROMATOGRAPHIC ANALYSIS; ETHERS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES; PHARMACOKINETICS; ULTRAVIOLET DETECTORS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANGIOGENESIS INHIBITOR; DRUG METABOLITE; PROTEIN TYROSINE KINASE INHIBITOR; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CALIBRATION; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CARCINOMA; LIGHT EXPOSURE; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL;

ANGIOGENESIS INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PYRROLES; REPRODUCIBILITY OF RESULTS;

EID: 72049088025     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.09.011     Document Type: Article

References (13)

1. Maluf F.C., Santos Fernandes G.D., Kann A.G., Aguilar-Ponce J.L., de la Garza J., and Buzaid A.C. Cancer Treat. Rev. (2008) 750
2. Lainakis G., and Bamias A. Curr. Cancer Drug. Targets 8 (2008) 349
3. Adams V.R., and Leggas M. Clin. Ther. 29 (2007) 1338
4. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., and Rini B.I. J. Clin. Oncol. 24 (2006) 16
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., and Figlin R.A. N. Engl. J. Med. 356 (2007) 115
6. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., and Raymond E. J. Clin. Oncol. 24 (2006) 25
7. Houk B.E., Amantea M., Motzer R.J., Michaelson M.D., Rini B.I., George D.J., Redman B.G., Hudes G.R., Poland B., and Bello C.L. ASCO 24 (2006) 4531
8. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., and Mahon F.X. Blood 109 (2007) 3496
9. Baratte S., Sarati S., Frigerio E., James C.A., Ye C., and Zhang Q. J. Chromatogr. A 1024 (2004) 87
10. Fiedler W., Serve H., Döhner H., Schwittay M., Ottmann O.G., O'Farrell A.M., Bello C.L., Allred R., Manning W.C., Cherrington J.M., Louie S.G., Hong W., Brega N.M., Massimini G., Scigalla P., Berdel W.E., and Hossfeld D.K. Blood 105 (2005) 986
11. Bello C.L., Sherman L., Zhou J., Verkh L., Smeraglia J., Mount J., and Klamerus K.J. Anticancer Drugs 17 (2006) 353
12. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., and Cherrington J.M. Clin. Cancer Res. 9 (2003) 327
13. Houk B.E., Bello C.L., Michaelson M.D., Bukowski R.M., Redman B.G., Hudes G.R., Wilding G., and Motzer R.J. ASCO (2007) 5027